

# Phase I Trial: 36676 (P2-101-301P)

<b>Submission date</b> 04/08/2025	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 04/08/2025	<b>Overall study status</b> Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 04/08/2025	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

## Contact information

### Type(s)

Public, Scientific

### Contact name

Dr Lynn Howard

### Contact details

Phase Pharmaceuticals LLC  
9425 Lenel Pl  
Dallas  
United States of America  
TX 75220  
+1 (0)917 683 1240  
lynn@phasepharma.com

### Type(s)

Principal investigator

### Contact name

Dr Annelize Koch

### Contact details

Simbec-Orion Clinical Pharmacology  
Merthyr Tydfil Industrial Park  
Cardiff Road  
Merthyr Tydfil  
United Kingdom

CF48 4DR  
+44 (0)1443694313  
annelize.koch@simbecorion.com

## Additional identifiers

**Integrated Research Application System (IRAS)**  
1012438

**Protocol serial number**  
P2-101-301P

## Study information

**Scientific Title**  
Phase I Trial: 36676 (P2-101-301P)

### Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Ethics approval required**  
Ethics approval required

### Ethics approval(s)

1. approved 14/07/2025, Wales Research Ethics Committee 2 (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44 (0)2922 941119; Wales.REC2@wales.nhs.uk), ref: 25.WA.0172
2. approved 21/07/2025, MHRA (MHRA, 10 South Colonnade, Canary Wharf, London, E14 4PU, United Kingdom; +44 (0)20 3080 6000; info@mhra.gov.uk), ref: CTA 59180/0001/001-0001

### Study design

Two-way crossover trial in up to 12 participants with known peanut hypersensitivity

**Primary study design**  
Interventional

**Study type(s)**  
Other, Safety, Efficacy

### Health condition(s) or problem(s) studied

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Intervention Type**

Drug

### **Phase**

Phase I

### **Drug/device/biological/vaccine name(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Primary outcome(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Key secondary outcome(s)**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Completion date**

03/11/2025

## **Eligibility**

### **Key inclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Participant type(s)**

Healthy volunteer

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Lower age limit**

18 years

### **Upper age limit**

55 years

**Sex**

All

**Key exclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Date of first enrolment**

05/08/2025

**Date of final enrolment**

20/10/2025

**Locations****Countries of recruitment**

United Kingdom

Wales

**Study participating centre****Simbec Research Limited**

Simbec House Merthyr Tydfil Industrial Park

Merthyr Tydfil Industrial Park

Pentrebach

Merthyr Tydfil

Mid Glamorgan

United Kingdom

CF48 4DR

**Sponsor information****Organisation**

Phase Pharmaceuticals LLC

**Funder(s)****Funder type**

Industry

**Funder Name**

## Results and Publications

### **Individual participant data (IPD) sharing plan**

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

### **IPD sharing plan summary**

Not expected to be made available